

6



07-30-01 518 Rec'd PCT/PTO 286 JUL 2001

**serono**

#6 mw

5460

1600

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED**

In re the application of: Koken, Marcel, et al

SEP 11 2001

Serial Number: 09/744,605

Group Art Unit: To be assigned TECH CENTER 1600/2900

Field: Jan. 26, 2001

Examiner: To be assigned

For: Use of Novel Agents Including Cell Death in Synergy with Interferons

**Information Disclosure Statement**  
**Pursuant to 37 CFR 1.97 (b)**

Assistant Commissioner of Patents  
Washington, D. C. 20231

July 25, 2001

\*\*\*\*\*

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date 7/26/01

By Diane Anderson

\*\*\*\*\*

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449A.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09/744,605
<b>Filing Date</b>	JAN 26, 2001
<b>First Named Inventor</b>	KOKEN
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	US471

*(use as many sheets as necessary)*

Sheet	1	of	3
-------	---	----	---

Attorney Docket Number US471

TECH CENTER 1600/2900

SEP 11 2001

RECEIVED

[illegible][illegible]

Date Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Worden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Compleat if Kn wn

Application Number	09/744,605
Filing Date	Jan. 26, 2001
First Named Inventor	Koken
Group Art Unit	
Examiner Name	
Attorney Docket Number	US 471

TECH CENTER 1600 2900

SEP 11 2001

RECEIVED

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	1	XIANG, BAX-induced cell death may not require interleukin 1 converting enzyme-like proteases, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 14559-14563, December 1996, Cell Biology
	2	QUIGNON, PML induces a novel caspase-independent death process, Nature Genetics, Vol. 20, pp. 259-265, November 1998
	3	VERCAMMEN, Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor, J. Exp. Med., The Rockefeller University Press, Vol. 187, No. 9, pp. 1477-1485, May 4, 1998
	4	GRIFFITH, CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance, Immunity, Vol. 5, pp. 7-16, July 1996
	5	VOLL, Immunosuppressive effect of apoptotic cells, Nature, Vol. 390, pp. 360-361, November 27, 1997
	6	GAO, Antiinflammatory Effects of CD 95 Ligand (FasL)-induced Apoptosis, J. Exp. Med., The Rockefeller University Press, Vol. 188, No. 5, pp. 887-896, September 7, 1998
	7	MELCHER, Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression, Nature Medicine, Vol. 4, No. 5, pp. 581-587, May 1998
	8	BYRD, Old and New Therapies in Chronic Lymphocytic Leukemia: Now Is the Time for a Reassessment of Therapeutic Goals, Seminars in Oncology, Vol. 24 (1), pp. 65-74, February 1998
	9	SOIGNET, Clinical and laboratory studies in leukemia of an organic arsenical melarsoprol, Proc. of ASCO, Vol. 16, pp. 4A, 1997
	10	KONIG, Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines, Blood, Vol. 90 (2), pp. 562-570, July 15, 1997

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

3

**O**

3

**Complete if Known**

Application Number

09/744,605

**Filing Date**

Jan. 26, 2001

**First Named Inventor**

KOKEN

### Group Art Unit

**Examiner Name**

Attorney Docket Number

US 471

#### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*Cite  
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

11

SLEE, Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. *Biochem. J.*, Vol. 315, pp. 21-24, 1996

**Examiner  
Signature**

Date \_\_\_\_\_  
Considered \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.